尼拉帕利治疗复发性卵巢癌的ENGOT-OV16/NOVA试验:生存与长期安全性
ENGOT-OV16/NOVA试验在延长随访和数据检索后,评估尼拉帕利维持治疗复发性卵巢癌的次要疗效终点和安全性。随机2:1分配至尼拉帕利300mg每日一次或安慰剂,97.6%(540/553)患者获得生存状态。gBRCA突变队列中位OS为40.9 vs 38.1个月(HR 0.85,95%CI 0.61-1.20),非gBRCA突变队列为31.0 vs 34.8个月(HR 1.06,95%CI 0.81-1.37),均无显著差异。预设次要终点数值上偏向尼拉帕利,长期安全性与已知特征一致。
要点
- gBRCA突变队列中位OS尼拉帕利组40.9个月 vs 安慰剂组38.1个月(HR 0.85,95%CI 0.61-1.20),无显著差异。
- 非gBRCA突变队列中位OS尼拉帕利组31.0个月 vs 安慰剂组34.8个月(HR 1.06,95%CI 0.81-1.37),无显著差异。
- 预设次要终点CFI、TFST、PFS2、TSST中位值在两组队列中均数值上偏向尼拉帕利,未发现新安全信号。
核心结论
- 尼拉帕利组与安慰剂组总生存无显著差异。
- 预设次要疗效终点数值上偏向尼拉帕利。
- 长期安全性与已知尼拉帕利安全性特征一致。
- 结合主要分析中观察到的PFS显著改善,这些数据支持尼拉帕利在复发性卵巢癌维持治疗中具有有利的总体获益-风险特征。
研究设计与样本
- ENGOT-OV16/NOVA(NCT01847274)试验,患者随机2:1分配至尼拉帕利(300 mg每日一次)或安慰剂。
- 延长生命状态核查以检索缺失生存数据患者的末次已知存活状态。
- 基于延长数据截止日期(2021年3月31日)报告预设次要疗效结局(OS、CFI、TFST、PFS2、TSST)和安全性。
- 97.6%(540/553)随机患者获得生存状态(gBRCA突变203例;非gBRCA突变350例)。
主要发现
- gBRCA突变队列中位OS尼拉帕利组40.9个月 vs 安慰剂组38.1个月(HR 0.85;95%CI 0.61-1.20)。
- 非gBRCA突变队列中位OS尼拉帕利组31.0个月 vs 安慰剂组34.8个月(HR 1.06;95%CI 0.81-1.37)。
- CFI、TFST、PFS2和TSST中位值在两个队列中均数值上偏向尼拉帕利。
- 未检测到新安全信号。
关键数值与推荐
- gBRCA突变队列中位OS:尼拉帕利组40.9个月 vs 安慰剂组38.1个月(HR 0.85;95%CI 0.61-1.20)。
- 非gBRCA突变队列中位OS:尼拉帕利组31.0个月 vs 安慰剂组34.8个月(HR 1.06;95%CI 0.81-1.37)。
- CFI、TFST、PFS2和TSST中位值在两个队列中均数值上偏向尼拉帕利。
临床怎么用
- 作者认为,结合主要分析中PFS的显著改善,这些数据支持尼拉帕利在复发性卵巢癌维持治疗中具有有利的总体获益-风险特征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate secondary efficacy endpoints and safety for the ENGOT-OV16/NOVA (NCT01847274) trial of niraparib maintenance therapy after extended follow-up and vital-status-data retrieval. Previously reported analyses (data cutoff, October 1, 2020) indicated benefit of niraparib maintenance therapy beyond first progression, but overall survival (OS) analyses were limited by missing data. METHODS: Patients were randomized 2:1 to niraparib (300 mg once daily) or placebo. A vital status check was extended to retrieve last-known-alive status for patients with missing survival data. Prespecified secondary efficacy outcomes (OS, chemotherapy-free interval [CFI], time to first subsequent therapy [TFST], PFS2, time to second subsequent therapy [TSST]) and safety are reported based on the extended data cutoff (March 31, 2021). RESULTS: Survival status was available for 97.6% (540/553) of randomized patients (germline BRCA [gBRCA]-mutated, 203; non-gBRCA-mutated, 350). Median OS with niraparib and placebo was 40.9 and 38.1 months, respectively, in the gBRCA-mutated cohort (hazard ratio [HR], 0.85; 95% confidence interval [CI], 0.61-1.20) and 31.0 and 34.8 months, respectively, in the non-gBRCA-mutated cohort (HR, 1.06; 95% CI, 0.81-1.37). Medians for CFI, TFST, PFS2, and TSST numerically favored niraparib in both cohorts. No new safety signals were detected. CONCLUSIONS: OS did not significantly differ between treatment arms. Prespecified secondary efficacy endpoints numerically favored niraparib. Long-term safety remained consistent with the established niraparib safety profile. Taken together with the significant improvements in PFS observed in the primary analysis, these data support a favorable overall benefit-risk profile for niraparib in the recurrent OC maintenance setting.
引用
- Matulonis UA, Herrstedt J, Oza A, et al. ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety. Gynecol Oncol. 2025. PMID: 40139026. doi:10.1016/j.ygyno.2025.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。